Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACH 301 phase II study of TYRA-300 in children with achondroplasia
ISRCTN77260709Phase 2Recruiting
- Sponsor
- Tyra Biosciences
- Start
- Aug 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of dabogratinib in achondroplasia (ACH) (3 cohorts), sponsored by Tyra Biosciences. Primary endpoints: Incidence of treatment-related adverse events and Change from baseline in annualized growth velocity. Started Aug 2025; status: recruiting.
02
Drugs
dabogratinib
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on ISRCTN77260709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN77260709.